View in EDS

Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01).

Saved in:

Bibliographic Details
Title:	Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01).
Authors:	Loong SL (AUTHOR), Hwang JS (AUTHOR), Li HH (AUTHOR), Wee JT (AUTHOR), Yap SP (AUTHOR), Chua ML (AUTHOR), Fong KW (AUTHOR), Tan TW (AUTHOR), Loong, Susan Li Er¹ (AUTHOR), Hwang, Jacqueline Siok Gek (AUTHOR), Li, Hui Hua (AUTHOR), Wee, Joseph Tien Seng (AUTHOR), Yap, Swee Peng (AUTHOR), Chua, Melvin Lee Kiang (AUTHOR), Fong, Kam Weng (AUTHOR), Tan, Terence Wee Kiat (AUTHOR)
Source:	Radiation Oncology. 2009, Vol. 4, p23-23. 1p.
Abstract:	Background: Over-expression of cyclooxygenase-2 (COX-2) enzyme has been reported in nasopharyngeal carcinoma (NPC). However, the prognostic significance of this has yet to be conclusively determined. Thus, from our randomized trial of radiation versus concurrent chemoradiation in endemic NPC, we analyzed a cohort of tumour samples collected from participants from one referral hospital.Methods: 58 out of 88 patients from this institution had samples available for analysis. COX-2 expression levels were stratified by immunohistochemistry, into negligible, weak, moderate and strong, and correlated with overall and disease specific survivals.Results: 58% had negligible or weak COX-2 expression, while 14% and 28% had moderate and strong expression respectively. Weak COX-2 expression conferred a poorer median overall survival, 1.3 years for weak versus 6.3 years for negligible, 7.8 years, strong and not reached for moderate. There was a similar trend for disease specific survival.Conclusion: Contrary to literature published on other malignancies, our findings seemed to indicate that over-expression of COX-2 confer a better prognosis in patients with endemic NPC. Larger studies are required to conclusively determine the significance of COX-2 expression in these patients. [ABSTRACT FROM AUTHOR]
	Copyright of Radiation Oncology is the property of BioMed Central and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Engineering Source

Be the first to leave a comment!